Loading...
Back to narrative

HCG: Fair Outlook Will Reflect Margin Gains And Governance Developments

KKR's Entry Will Enable Expansion Of Precision Oncology And Fertility Services

HCG logo
HCG
AnalystConsensusTarget
Not Invested
Published 24 Jan 2025

Update shared on 05 Dec 2025

Fair value Increased 12%
Previous
n/a
n/a
AnalystConsensusTarget's Fair Value
n/a
Loading
1Y
40.8%
7D
1.9%

Analysts have raised their price target on HealthCare Global Enterprises by approximately ₹81 to reflect slightly faster expected revenue growth, improved profit margins, and a modestly lower future price to earnings multiple in their updated valuation model.

What's in the News

  • The board has scheduled a meeting for December 01, 2025, to formally appoint Chief Internal Auditor Vijay S Shanbhag as Internal Auditor for a 6 month term under Section 138 of the Companies Act, 2013 (board filing).
  • A board meeting on November 12, 2025, will review unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (board filing).
  • The same November 12, 2025, meeting will consider investing up to 10 percent in Cancer Care Kenya Limited, a step down subsidiary, and issuing a standby letter of credit guarantee to support its expansion related credit facilities (board filing).
  • CVC Capital Partners is preparing a block deal that would fully exit its remaining stake in HealthCare Global Enterprises, after earlier selling a 54 percent controlling stake to KKR in February 2025 (market reports).

Valuation Changes

  • Fair Value: risen moderately from approximately ₹693 to ₹774 per share, reflecting higher long term earnings expectations.
  • Discount Rate: increased marginally from 12.73 percent to 12.76 percent, implying a slightly higher required return for equity holders.
  • Revenue Growth: edged up from about 14.78 percent to 14.91 percent annually, indicating a small uplift in top line growth assumptions.
  • Net Profit Margin: increased meaningfully from roughly 8.29 percent to 9.25 percent, signalling improved profitability expectations.
  • Future P/E: reduced modestly from about 47.95x to 46.71x, suggesting a slightly lower valuation multiple applied to future earnings.

Have other thoughts on HealthCare Global Enterprises?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.